Drug profile · INN
sugemalimab
CEJEMLY
sugemalimab (CEJEMLY) is a programmed cell death 1 ligand 1 binding agent.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01FF11
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — sugemalimab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
sugemalimab (CEJEMLY) is a programmed cell death 1 ligand 1 binding agent.
Key facts
INN sugemalimab
Brand CEJEMLY
Mechanism Programmed cell death 1 ligand 1 binding agent
Target Programmed cell death 1 ligand 1
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FF11
Mechanism of action
Programmed cell death 1 ligand 1 binding agent
Primary target: Programmed cell death 1 ligand 1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is sugemalimab?
sugemalimab (CEJEMLY) is a programmed cell death 1 ligand 1 binding agent.
What is the brand name for sugemalimab?
CEJEMLY is a marketed brand name for sugemalimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.